



**VIJAYA  
DIAGNOSTIC  
CENTRE**

February 4, 2022

To,  
Listing Department  
National Stock Exchange of India Limited,  
Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East), Mumbai- 400 051  
Company Code No. VIJAYA

To,  
The Corporate Relations Department  
BSE Limited,  
Phiroz Jeejeebhoy Towers,  
25<sup>th</sup> Floor, Dalal Street  
Mumbai- 400 001  
Company Code No. 543350

Dear Sir/Madam,

**Sub: Intimation of Press Release.**

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the "Press Release" as mentioned below;

" Vijaya Diagnostic Centre Limited declares robust performance for 9MFY22 with a Revenue growth of 31% and PAT growth of 62%"

Please take the information on record.

Thanking you,

**For Vijaya Diagnostic Centre Limited**

**Anusha Kanumuru  
Company Secretary**



## Press Release

### Vijaya Diagnostic Centre Limited declares robust performance for 9MFY22 with a Revenue growth of 31% and PAT growth of 62%

**Hyderabad, India, February 4, 2022** - Vijaya Diagnostic Centre Limited (NSE: VIJAYA, BSE: 543350) one of the India's leading integrated diagnostic chain has announced its Financial Results for the quarter and nine months ended 31<sup>st</sup> December 2021.

#### Consolidated Financial Performance:

Particulars (Rs. Mn)	Q3FY22	Q3FY21	YoY	9MFY22	9MFY21	YoY
Revenue from Operations	1,108	999	11%	3,462	2,647	31%
EBITDA	478	464	3%	1,558	1,116	40%
EBITDA Margin (%)	43.2%	46.5%		45.0%	42.1%	
Profit after Tax	253	247	2%	860	531	62%

#### Performance Highlights 9MFY22:

- Revenue from Operations increased by 31% YoY to Rs. 3,462 Mn
- Non-COVID revenue grew by 39% YoY from Rs. 2,121 Mn in 9MFY21 to Rs. 2,947 Mn in 9MFY22 while COVID & COVID allied revenue (RT-PCR, Antibody tests and COVID allied tests like IL-6 and D- Dimer) declined by 2% YoY to Rs. 514 Mn
- Revenue from B2C segment stood at 94% of total revenue
- EBITDA stood at Rs. 1,558 Mn, an increase of 40% over corresponding previous period; EBITDA margin was 45.0%
- PAT increased by 62% YoY to Rs. 860 Mn vs. Rs. 531 Mn in the corresponding previous period
- The company added 9 centres including 3 hub centres and 1 reference lab, taking the total centre count to 89 and the total reference lab count to 12 as on 31<sup>st</sup> December 2021

#### Performance Highlights Q3FY22:

- Revenue from Operations increased by 11% YoY to Rs. 1,108 Mn
- Non-COVID revenue grew by 20% YoY to Rs. 1,022 Mn and COVID & COVID allied revenue (RT-PCR, Antibody tests and COVID allied tests like IL-6 and D- Dimer) declined 40% YoY to Rs. 86 Mn
- EBITDA stood at Rs. 478 Mn, an increase of 3% over the corresponding previous quarter. EBITDA margin for the quarter was 43.2%
- PAT increased by 2% YoY to Rs. 253 Mn
- Expanded by adding 4 centres including 2 hub centres and 1 reference lab in Q3FY22



# VIJAYA DIAGNOSTIC CENTRE

**Commenting on the performance Ms. Suprita Reddy, CEO said,** *“This quarter, we have added 4 centres that are fully equipped with the state-of-the-art equipment, technology and professional expertise. These new centres comprise of 2 hubs, and 1 reference lab that are capable of providing the best diagnostic services. We have also partnered with reputed corporate organizations for providing comprehensive health and wellness services for their employees and their families. We are also working towards digitizing our business processes to optimize operational efficiency and enable the best possible customer experience.*

*Our operating revenue grew by 31% YoY to Rs. 3,462 Mn in first nine months of FY22. EBIDTA increased by 40% YoY to Rs. 1,558 Mn. Our profitability during the nine months period of Rs. 860 Mn was also higher than the profitability of the entire last financial year.*

*We will continue to maintain and strengthen our hold in core geographies by strategically expanding. In addition to this, our focus for the near future would be to selectively expand in East India.”*

## About Vijaya Diagnostic Centre Limited (VDCL)

Vijaya Diagnostic Centre Limited (VDCL), is the largest integrated diagnostic chain having dominant presence in Southern India. Vijaya provides one-stop solution for pathology and radiology testing services to customers through extensive operational network, which consists of 89 diagnostic centres and 12 reference laboratories across 15 cities and towns in the states of Telangana and Andhra Pradesh and in the National Capital Region and Kolkata. The Company offers comprehensive range of diagnostic services from Basic pathology to high-end radiology.

## Safe Harbor Statement

This document may contain forward-looking statements about the Company, which are based on the beliefs, opinions and expectations of the Company’s management as the date of this press release and the companies do not assume any obligation to update their forward looking statements if those beliefs, opinions, expectations, or other circumstances should change, these statements are not the guarantees of future performance and involve risks and uncertainties that are difficult to predict. Consequently, readers should not place any undue reliance on such forward-looking statements.

**For more Information, please contact:**

**Mr. Krishna Kiran**  
Investor Relations  
Vijaya Diagnostic Centre Limited  
Phone: +91 90597 00749  
Email: [ir@vijayadiagnostic.in](mailto:ir@vijayadiagnostic.in) /  
[krishnakiran@vijayadiagnostic.in](mailto:krishnakiran@vijayadiagnostic.in)

**Ms. Irfan Raeen**  
Orient Capital (a division of Link Group)  
Phone: +91 97737 78669  
Email: [irfan.raeen@linkintime.co.in](mailto:irfan.raeen@linkintime.co.in)